ICON Public (NASDAQ:ICLR) Given New $330.00 Price Target at Barclays

ICON Public (NASDAQ:ICLR) had its price objective dropped by equities research analysts at Barclays from $350.00 to $330.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective would indicate a potential upside of 11.45% from the stock’s current price.

ICLR has been the topic of a number of other reports. Evercore ISI decreased their price target on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Redburn Atlantic initiated coverage on ICON Public in a report on Monday. They set a “neutral” rating and a $311.00 price target on the stock. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Finally, Truist Financial reduced their price objective on shares of ICON Public from $383.00 to $363.00 and set a “buy” rating on the stock in a research report on Monday. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $346.09.

ICON Public Price Performance

Shares of ICLR stock traded down $0.45 during trading on Tuesday, hitting $296.10. The company had a trading volume of 165,567 shares, compared to its average volume of 571,543. ICON Public has a 52 week low of $221.20 and a 52 week high of $347.72. The stock has a market capitalization of $24.43 billion, a price-to-earnings ratio of 36.02, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average is $304.99 and its two-hundred day moving average is $313.14.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, beating the consensus estimate of $3.68 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.14 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $2.96 EPS. As a group, analysts predict that ICON Public will post 14.54 EPS for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of ICON Public by 22.5% in the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after buying an additional 32 shares in the last quarter. Steph & Co. lifted its stake in shares of ICON Public by 11.2% in the 1st quarter. Steph & Co. now owns 1,852 shares of the medical research company’s stock valued at $622,000 after purchasing an additional 186 shares during the last quarter. Riverview Trust Co purchased a new position in shares of ICON Public in the 1st quarter worth approximately $31,000. Arkadios Wealth Advisors bought a new position in shares of ICON Public during the 1st quarter valued at approximately $247,000. Finally, Whittier Trust Co. raised its holdings in ICON Public by 21.9% during the 1st quarter. Whittier Trust Co. now owns 3,295 shares of the medical research company’s stock valued at $1,107,000 after buying an additional 593 shares during the period. 95.61% of the stock is owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.